These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22720661)

  • 1. Lymphedema of the breast as a symptom of internal diseases or side effect of mTor inhibitors.
    Hille U; Soergel P; Makowski L; Dörk-Bousset T; Hillemanns P
    Lymphat Res Biol; 2012 Jun; 10(2):63-73. PubMed ID: 22720661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
    Sánchez-Fructuoso AI; Ruiz JC; Pérez-Flores I; Gómez Alamillo C; Calvo Romero N; Arias M
    Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteinuria associated with mTOR inhibitors after kidney transplant.
    Guney M; Sahin G; Yilmaz B; Canbakan M; Gucun M; Kayatas K; Eren P; Titiz I
    Exp Clin Transplant; 2014 Dec; 12(6):539-42. PubMed ID: 25489805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and treatment of lymphedema in heart transplant patients treated with everolimus.
    Ribezzo M; Boffini M; Ricci D; Barbero C; Bonato R; Attisani M; Pasero D; Rinaldi M
    Transplant Proc; 2014 Sep; 46(7):2334-8. PubMed ID: 25242782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus: a new hope for patients with breast cancer.
    Sendur MA; Zengin N; Aksoy S; Altundag K
    Curr Med Res Opin; 2014 Jan; 30(1):75-87. PubMed ID: 24050600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pros and the cons of mTOR inhibitors in kidney transplantation.
    Ponticelli C
    Expert Rev Clin Immunol; 2014 Feb; 10(2):295-305. PubMed ID: 24377908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure.
    Massarweh S; Romond E; Black EP; Van Meter E; Shelton B; Kadamyan-Melkumian V; Stevens M; Elledge R
    Breast Cancer Res Treat; 2014 Jan; 143(2):325-32. PubMed ID: 24327334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interstitial pneumonitis as an adverse reaction to mTOR inhibitors.
    Molas-Ferrer G; Soy-Muner D; Anglada-Martínez H; Riu-Viladoms G; Estefanell-Tejero A; Ribas-Sala J
    Nefrologia; 2013; 33(3):297-300. PubMed ID: 23712219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus in clinical practice in long-term liver transplantation: an observational study.
    Casanovas T; Argudo A; Peña-Cala MC
    Transplant Proc; 2011; 43(6):2216-9. PubMed ID: 21839237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus: targeted therapy on the horizon for the treatment of breast cancer.
    Barnett CM
    Pharmacotherapy; 2012 Apr; 32(4):383-96. PubMed ID: 22461124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation.
    Nguyen LS; Vautier M; Allenbach Y; Zahr N; Benveniste O; Funck-Brentano C; Salem JE
    Drug Saf; 2019 Jul; 42(7):813-825. PubMed ID: 30868436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk evaluation and mitigation strategies: a focus on the mammalian target of rapamycin inhibitors.
    Gabardi S
    Prog Transplant; 2013 Mar; 23(1):55-7. PubMed ID: 23448821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Refractory autoimmune hemolytic anemia after intestinal transplant responding to conversion from a calcineurin to mTOR inhibitor.
    Acquazzino MA; Fischer RT; Langnas A; Coulter DW
    Pediatr Transplant; 2013 Aug; 17(5):466-71. PubMed ID: 23730873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal function preservation with the mTOR inhibitor, Everolimus, after lung transplant.
    Schneer S; Kramer MR; Fox B; Rusanov V; Fruchter O; Rosengarten D; Bakal I; Medalion B; Raviv Y
    Clin Transplant; 2014 Jun; 28(6):662-8. PubMed ID: 24738962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can patients maintain their use of everolimus until lung transplantation?
    Costa AN; Baldi BG; de Oliveira Braga Teixeira RH; Samano MN; de Carvalho CR
    Transplantation; 2015 Jun; 99(6):e42-3. PubMed ID: 26035277
    [No Abstract]   [Full Text] [Related]  

  • 16. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.
    Gabardi S; Baroletti SA
    Pharmacotherapy; 2010 Oct; 30(10):1044-56. PubMed ID: 20874042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus: efficacy and safety in cardiac transplantation.
    Schaffer SA; Ross HJ
    Expert Opin Drug Saf; 2010 Sep; 9(5):843-54. PubMed ID: 20701555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lymphedema in patients treated with sirolimus: 15 cases].
    Fourgeaud C; Simon L; Benoughidane B; Vignes S
    Rev Med Interne; 2019 Mar; 40(3):151-157. PubMed ID: 29752013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.
    Somers MJ; Paul E
    J Clin Pharmacol; 2015 Apr; 55(4):368-76. PubMed ID: 25402866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma.
    Grgic T; Mis L; Hammond JM
    Ann Pharmacother; 2011 Jan; 45(1):78-83. PubMed ID: 21177421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.